Literature DB >> 14728841

[Changes and significance of orphanin and serotonin in patients with postpartum depression].

Hang Gu1, Dian Hu, Xin-ru Hong, Jie Mao, Ying Cui, Ning Hui, Jin-yan Sha.   

Abstract

OBJECTIVE: To study the changes of orphanin (OFQ) and serotonin (5-HT) in the patients with postpartum depression (PPD).
METHODS: Twenty one patients with postpartum depression (PPD group) and 25 healthy lying-in women (control group) were studied. The concentrations of plasma OFQ were measured by radioimmunoassay. The levels of 5-HT were measured with high-pressure liquid chromatography with electrochemical detector.
RESULTS: (1) The levels of plasma OFQ in PPD group were (28.5 +/- 5.8) ng/L, in control group, the levels of OFQ was (10.4 +/- 3.7) ng/L, the levels of OFQ in PPD group were significantly higher than that in the control group (P < 0.01). (2) The levels of plasma 5-HT in PPD group and control group were (1.0 +/- 0.3) micro mol/L and (1.4 +/- 0.4) micro mol/L respectively, the levels of 5-HT in PPD group decreased significantly (P < 0.05). (3) In the PPD group, there was a significant negative correlation between the OFQ and 5-HT level (P < 0.05).
CONCLUSION: The PPD was associated with OFQ and 5-HT, the changes of OFQ levels may play an important role in the pathogenesis of the PPD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14728841

Source DB:  PubMed          Journal:  Zhonghua Fu Chan Ke Za Zhi        ISSN: 0529-567X


  7 in total

1.  Endogenous nociceptin/orphanin-FQ in the dorsal hippocampus facilitates despair-related behavior.

Authors:  Celia Goeldner; David Reiss; Brigitte L Kieffer; Abdel-Mouttalib Ouagazzal
Journal:  Hippocampus       Date:  2010-08       Impact factor: 3.899

2.  Social defeat disrupts reward learning and potentiates striatal nociceptin/orphanin FQ mRNA in rats.

Authors:  Andre Der-Avakian; Manoranjan S D'Souza; David N Potter; Elena H Chartoff; William A Carlezon; Diego A Pizzagalli; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2017-03-09       Impact factor: 4.530

Review 3.  Antidepressant- and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands.

Authors:  Elaine C Gavioli; Girolamo Calo'
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-02-21       Impact factor: 3.000

Review 4.  The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.

Authors:  Jeffrey M Witkin; Michael A Statnick; Linda M Rorick-Kehn; John E Pintar; Michael Ansonoff; Yanyun Chen; R Craig Tucker; Roberto Ciccocioppo
Journal:  Pharmacol Ther       Date:  2013-11-01       Impact factor: 12.310

5.  A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies.

Authors:  Anke Post; Trevor S Smart; Judith Krikke-Workel; Gerard R Dawson; Catherine J Harmer; Michael Browning; Kimberley Jackson; Rishi Kakar; Richard Mohs; Michael Statnick; Keith Wafford; Andrew McCarthy; Vanessa Barth; Jeffrey M Witkin
Journal:  Neuropsychopharmacology       Date:  2015-11-20       Impact factor: 7.853

6.  Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors.

Authors:  Jeffrey M Witkin; Linda M Rorick-Kehn; Mark J Benvenga; Benjamin L Adams; Scott D Gleason; Karen M Knitowski; Xia Li; Steven Chaney; Julie F Falcone; Janice W Smith; Julie Foss; Kirsti Lloyd; John T Catlow; David L McKinzie; Kjell A Svensson; Vanessa N Barth; Miguel A Toledo; Nuria Diaz; Celia Lafuente; Alma Jiménez; Alfonso Benito; Conception Pedregal; Maria A Martínez-Grau; Anke Post; Michael A Ansonoff; John E Pintar; Michael A Statnick
Journal:  Pharmacol Res Perspect       Date:  2016-11-07

Review 7.  Role of nociceptin/orphanin FQ and nociceptin opioid peptide receptor in depression and antidepressant effects of nociceptin opioid peptide receptor antagonists.

Authors:  Jong Yung Park; Suji Chae; Chang Seop Kim; Yoon Jae Kim; Hyun Joo Yi; Eunjoo Han; Youngshin Joo; Surim Hong; Jae Won Yun; Hyojung Kim; Kyung Ho Shin
Journal:  Korean J Physiol Pharmacol       Date:  2019-10-24       Impact factor: 2.016

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.